Effect of Hematocrit Level on the PL50 and NA50
. | Compounds . | n . | IC50 (μmol/L) . | PC50 (μmol/L) . | PE50 (μmol/L) . | NA50 (μmol/L) . | Hematocrit Level Effect . |
---|---|---|---|---|---|---|---|
B4 | C12H25-NH-CH(C2H5)-CH2OH | 12 | 0.61 | 7.2 | 5 | 7.5 | Yes |
67 | 36 | 44 | |||||
E4 | C10H21-N+(CH3)3 | 10 | 0.7 | 5 | 80 | 145 | No |
9.5 | 115 | 200 | |||||
E6 | C12H25-N+(CH3)3 | 12 | 0.5 | 3.2 | 8 | 8.5 | Yes |
12 | 25 | 300 | |||||
E7 | C14H29-N+(CH3)3 | 14 | 0.9 | 1.8 | 2.9 | 4.6 | Yes |
18 | 16 | 18 | |||||
E40 | C14H29-H+(CH3)2-CH2Φ | 14 | 1 | 5.5 | 4.4 | 2 | Yes |
22 | 27 | 19 | |||||
E8 | C16H33-N+(CH3)3 | 16 | 0.8 | 2.6 | 2.2 | 6.6 | Yes |
21 | 23 | 44 | |||||
F3 | C10H21-N+(CH3)2-(CH2)2OH | 10 | 0.97 | 7 | 33 | 62 | No |
18 | 78 | 90 | |||||
F4 | C12H25-N+(CH3)2-(CH2)2OH | 12 | 0.48 | 2.2 | 12 | 8 | No |
6.5 | 28 | 19 | |||||
F5 | C14H29-N+(CH3)2-(CH2)2OH | 14 | 0.6 | 5.5 | 5.1 | 11.5 | Yes |
47 | 43 | 75 | |||||
F9 | C14H29-N+(C2H5)2-(CH2)2OH | 14 | 0.55 | 3.7 | 5.7 | 6.8 | Yes |
26 | >30 | >30 | |||||
F6 | C18H37-N+(CH3)3 | 18 | 1.3 | 6 | 7.5 | 5.2 | Yes |
24 | 48 | 28 | |||||
G3 | (CH3)3N+-C10H21-N+(CH3)3 | 10 | 1.7 | 12 | >200 | >200 | No |
16 | >200 | >200 | |||||
G4 | (CH3)3N+-C12H25-N+(CH3)3 | 12 | 0.09 | 4.8 | >20 | >20 | No |
6 | >20 | >20 |
. | Compounds . | n . | IC50 (μmol/L) . | PC50 (μmol/L) . | PE50 (μmol/L) . | NA50 (μmol/L) . | Hematocrit Level Effect . |
---|---|---|---|---|---|---|---|
B4 | C12H25-NH-CH(C2H5)-CH2OH | 12 | 0.61 | 7.2 | 5 | 7.5 | Yes |
67 | 36 | 44 | |||||
E4 | C10H21-N+(CH3)3 | 10 | 0.7 | 5 | 80 | 145 | No |
9.5 | 115 | 200 | |||||
E6 | C12H25-N+(CH3)3 | 12 | 0.5 | 3.2 | 8 | 8.5 | Yes |
12 | 25 | 300 | |||||
E7 | C14H29-N+(CH3)3 | 14 | 0.9 | 1.8 | 2.9 | 4.6 | Yes |
18 | 16 | 18 | |||||
E40 | C14H29-H+(CH3)2-CH2Φ | 14 | 1 | 5.5 | 4.4 | 2 | Yes |
22 | 27 | 19 | |||||
E8 | C16H33-N+(CH3)3 | 16 | 0.8 | 2.6 | 2.2 | 6.6 | Yes |
21 | 23 | 44 | |||||
F3 | C10H21-N+(CH3)2-(CH2)2OH | 10 | 0.97 | 7 | 33 | 62 | No |
18 | 78 | 90 | |||||
F4 | C12H25-N+(CH3)2-(CH2)2OH | 12 | 0.48 | 2.2 | 12 | 8 | No |
6.5 | 28 | 19 | |||||
F5 | C14H29-N+(CH3)2-(CH2)2OH | 14 | 0.6 | 5.5 | 5.1 | 11.5 | Yes |
47 | 43 | 75 | |||||
F9 | C14H29-N+(C2H5)2-(CH2)2OH | 14 | 0.55 | 3.7 | 5.7 | 6.8 | Yes |
26 | >30 | >30 | |||||
F6 | C18H37-N+(CH3)3 | 18 | 1.3 | 6 | 7.5 | 5.2 | Yes |
24 | 48 | 28 | |||||
G3 | (CH3)3N+-C10H21-N+(CH3)3 | 10 | 1.7 | 12 | >200 | >200 | No |
16 | >200 | >200 | |||||
G4 | (CH3)3N+-C12H25-N+(CH3)3 | 12 | 0.09 | 4.8 | >20 | >20 | No |
6 | >20 | >20 |
The PL50 and NA50 were measured and expressed as in Table 1. Experiments were performed as described in Fig2, ie, either at low hematocrit level (2.5 × 106infected cells/300 μL final volume) or at a 10-fold higher hematocrit level (5 × 106 infected cells/60 μL final volume). Values in italics correspond to measurements performed at the lowest hematocrit level (usually between 1.1% and 3%). Yes indicates an effect of hematocrit level on metabolic activity inhibition and no is the opposite; n corresponds to the number of carbons present in the long alkyl chain.